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A 77-year-old man with abdominal aortic aneurysm (AAA) was referred to our depart- 
ment. His AAA, which was 6 cm in diameter, was found incidentally with ttltrasonogra- 
phy. On admission the diagnosis of  hemophilia A was made for the first time in his life 
became activated partial thromboplastin time was decreased to 32.3% and factor V I I I  
coagulant activity was 2.1% (normal range 40% to 140%). Recombinant factor V I I I  
supplemental therapy was continued during surgery to maintain his factor V I I I  level 
within the normal range. His AAA was operated successfully with bifurcated graft 
replacement. NO unusual bleeding complications occurred during his hospitalization. 
With proper preparation the patient with AAA and hemophilia A can safely undergo 
surgical treatment. Three other cases of  AAA with hemophilia in the English literature 
were reviewed, and this is the oldest patient with hemophilia who underwent AAA 
surgery. (J Vase Surg 1997;25:945-8.) 
Hemophil ia A is an inherited coagulant disorder 
caused by deficiency o f  coagulant factor VI I I .  Dur- 
ing the past 3 decades urgery in patients with hemo- 
philia A has been accomplished more safely with the 
development of  blood concentrated factor V I I I3  ,2 
Recombinant factor V I I I  is especially beneficial be- 
cause of  its virus-free nature. Many surgical cases 
with hemophilia A have been reported, but aortic 
vascular surgery is still rare. a-s In this article we 
present a case o f  abdominal aortic aneurysm (AAA) 
with hemophilia A, and the management o f  hemo- 
stasis during surgery is described. 
CASE REPORT 
A 77-year-old man was referred to our hospital for the 
treatment of AAA, which was found incidentally with ultra- 
sonography. He had noticed his bleeding tendency in his 
20s, when one episode of excessive bleeding occurred after 
extraction of his tooth He had not, however, been given 
From the First Department of Surgery and the Department of 
Transfusion Medicine, Nagoya University School of Medicine 
and Nagoya University Hospital. 
Reprint requests: MasayQshi Kobayashi, MD, The First Depart- 
ment of Surgery, Nagoya University School of Medicine, 65 
Tsurumal-chou, Shouwa-ku, Nagoya, 466, l pan. 
Copyright © 1997 by TheSociety for Vascular Surgery and Inter- 
national Society for Cardiovascular Surgery, North American 
Chapter. 
0741-5214/97/$5.00 + 0 24/4/78610 
the diagnosis of coagulation disorder. That was the only 
episode of bleeding until he was admitted to our hospital. 
On admission routine coagulant tests showed slightly 
decreased platelet count (131,000/ixl) and prolonged ac- 
tivated partial thromboplastin time (32.3% of control). 
Factor VIII activity and factor VIII inhibitor were addi- 
tionally ordered and proved to be as low as 2.1% (normal 
40% to 140%) and 0%, respectively. On the basis of this 
result the diagnosis of hemophilia A was made. 
Computed tomography showed his aneurysm was lo- 
cated between just below the renal arteries and bilateral 
iliac bifurcation, which contained mural thrombus. The 
maximal diameter was 6 cm. Angiography was performed 
with Seldginger's method through t e left brachial artery 
under supplemental therapy, which revealed that the origin 
of the right renal artery was slightly stenotic. Severe athero- 
sclerotic lesions were found in the bilateral external and 
internal iliac arteries. Two thousands units of purified re- 
combinant factor VIII (Kogenate) was administered by a 
bolus shot 30 minutes before the procedure was per- 
formed, and 1000 U was added 30 minutes after the 
procedure was performed. The factor VIII function level 
was increased up to 109.3% at 30 minutes after the proce- 
dure and to 90.3% at 2 hours later. No bleeding complica- 
tion was related to this procedure. On the basis of this 
result he dosage of factor VIII replacement therapy for the 
perioperative course was determined. 
On September 7, 1995, aortobifemoral graft replace- 
ment was performed in the usual manner with a 16 × 8 
mm albumin-coated bifurcated graft. Three thousand units 
of heparin and 300 ml mannitol were administered before 
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Fig. 1. Microscopic view ofaneurysm (hematoxylin-eosin 
staining, ×40). Fibrointimal tissue and hyaline degenera- 
tion in media and adventitial cell infiltration are shown. 
Vaso vasurums are slightly dilated; however, there is no 
specific findings as hemophiliac aneurysm. On histologic 
evaluation this hemophiliac aneurysm is not different from 
that of nonhemophiliac neurysm. 
aortic clamping was performed. After anastomosis was 
completed, 30 mg protamin sulfate was given to reverse 
hcparinization. No excessive bleeding occurred, and the 
total blood loss was 1303 ml, which was replaced with 2 U 
of stored red blood cells. Soon after thc operation throm- 
bosis of the left superficial femoral artery was found, and it 
was treated successfully by thrombectomy with a balloon 
catheter. 
A small amount of red thrombus was in the aneurysm. 
It was quite different from the thrombi usually found in an 
arteriosclerotic aneurysm. However, the inner surface of 
the aneurysm looked similar to a typical arteriosclerotic 
aneurysm. On histologic evaluation it was reported that 
the aneurysm wall was not different from that of patients 
without hemophili a (Fig. 1). 
In terms of factor VIII supplemental therapy, 3000 U 
of factor VIII (60/kg) was given 3 hours before surgery, 
and 2000 U was replenished when heparin was reversed. 
Just after the operation 3000 U was administered by bolus 
injection. Five thousand units per day (4 U/kg/hr)  of 
purified factor VIII was administered with a continuous 
infusion pump to keep the factor VIII activity level at more 
than 100% for 3 days, and 3000 U/day (2.5 U/kg/hr)  
was administered for the next 7 days to maintain its level 
between 80% and 100%. Syringes were changed every 
1000 U because the half period of factor VIII solution was 
considered 17.7 + 7.2 hours, and possible bacterial con- 
tamination was to be avoided. The doses of factor VIII 
were decreased step by step and were switched to bolus 
injection for 7 days. In total, the patient received 54,000 U 
of factor VIII for 18 days (Fig. 2). The response of factor 
VIII activity, its inhibitor, prothrombin time, and activated 
partial thromboplastin time to administration of recombi- 
nant purified factor VIII were monitored uring his hospi- 
talization. No bleeding episodes were observed uring his 
hospit .alization. Postoperative intravenous digital subtrac- 
tion angiography showed good patency of the replaced 
graft. 
DISCUSSION 
As far as we researched in the English literature, 
only three AAA cases were found with hemophilia; 
two were hemophilia A and one was hemophilia B. 
All were successfully treated with surgery 1,6,7 (Table 
I). Our  case is the oldest patient with hemophilia A 
who had graft replacement surgery. For the treat- 
ment o f  AAA an endovascular procedure was devel- 
oped recently; however, surgical graft replacement is 
still a standard option. 
Even in a patient without hcmophilia AAA is 
known to bca  cause of  coagulation disorder. There 
are many reports o f  excessive bleeding complications. 
Therefore it is absolutely necessary in patients with 
AAA and hemophilia to evaluate and correct periop- 
erative hemostatic activity. In this case recombinant 
factor VI I I ,  which is the newest product o f  commer- 
cial factor V I I I  concentrates, was used to supply the 
lacldng factor. Before we performed the surgical pro- 
cedure on AAA, we performed a factor V I I I  survival 
study during angiography and estimated that factor 
V I I I  function levels were raised by approximately 2% 
in vivo with a preparation of  1 U /kg  factor VI I I .  On 
the basis o f  this result and the formula the dosage of  
factor V I I I  replacement therapy for the perioperative 
course was calculated and determined. The dosage 
for factor V I I I  in U = (B - A ) /100  × Wt × 103 X 
1 /13  X (100 - Ht)  x 1 /100 ,  where A is the 
patient's factor V I I I  level (%), B is the factor V I I I  
level needed for hemostasis (%), Wt is the patient's 
body weight, and Ht  is the hematocrit level (%). In 
this case 5385.6 U o f  factor V I I I  was calculated to 
get the factor V I I I  level o f  200%. Two hundred 
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Fig. 2. Administered factor VIII concentrates and plasma level of factor VIII during perioper- 
ative course. Factor VIII level was kept at more than 100% during first 3 days and at 80% to 
100% for next 7 days and decreased step by step. Factor VIII was administered with use of 
continuous infusion for first 10 days and with bolus injection for next 7 days. 
Table I. Profiles of hemophiliac patient with AAA 
Case Age Severity of Amount of factor 
no. Authors (yr) Sex Operation Hemophilia hemophilia replacement (U) Days treated Treatment 
1 Gula 7 55 Male Bifurcated graft B Moderate 17500, F IX 8 Bolus shot 
replacement 
2 Brown 1 67 Male Resection of  A Moderate 54850, F VIII I6 Bolus shot 
AAA 
3 Bergqvist 6 66 Male Bifurcated graft A Mild 52000, F VIII 18 Bolus shot 
replacement 
4 Present case 77 Male Bifurcated graft A Moderate 54000, F VIII 18 Bolus + continuous 
replacement 
percent of the factor VI I I  levels may have been too 
high; however, our hematologist uggested that vas- 
cular surgery such as in this case would require ap- 
proximately 5000 U/day  for the first 3 or 4 days. 
After surgery factor VI I I  was administered with the 
use of continuous infusion for the first" 10 days and 
with the bolus injection for the next 7 days. The use 
of a constant infusion of supplemental therapy 
seemed to be safe, efficacious, and more convenient. 
From the point of half-life of the recombinant factor 
VI I I  and bacterial contamination, the syringes were 
changed after every 1000 U. With adequate coagu- 
lant replacement therapy we were able to obtain 
sufficient hemostasis during the perioperative period. 
Three reported cases were given coagulant factor 
concentrates xtracted from human plasma, and sur- 
gery was performed without excess blceding prob- 
lems. 
This case was the first time a surgical procedure 
was performed on AAA in a patient with hemophilia 
A. We may have been very careful to taper the dosage 
of factor VII I .  We believe that if we have another 
case, the treatment period can be shorter than in this 
case.  
Infectious complications from transfusion-tran,;- 
mittcd viruses such as hepatitis B and C and the 
human immunodeficiency virus have been reported 
in patients with hemophilia for 3 decades. 8-1° In a 
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recent report Triemstra et al.~l reported that the 
acquired immunodeficiency syndrome and hepatitis 
strongly influence mortality in patients with hemo- 
philia. Our patient, however, had not been given the 
diagnosis of hemophilia A and had never been 
treated with potentially infected medication. This 
may have allowed the patient to live a longer life than 
patients with hemophilia who received such treat- 
ment. Now many newer types of factor concentrates 
have been developed both to eliminate infectious 
side effect and to increase purity. 12-14 It has been 
reported that in the absence of viral infections the life 
expectancy of patients with hemophilia would almost 
equal that of the general male population, n There- 
fore more patients with hemophilia will survive long 
enough to get atherosderotic disease. 
In this particular case it is interesting that a small 
amount of red mural thrombus was in the aneurysm 
despite the deficiency of coagulant factor VIII. This 
thrombus was far different from the usual one. Two 
of the three reported incidences of aneurysm with 
hemophilia did not have mural thrombus at all. One 
has no description. Taldng into account the fact that 
thrombosis occurred just after surgery, when the 
factor VIII level was supplemented as high as normal, 
hemophilia may block the formation of pathologic 
arterial thrombus. Sullivan et al. ~S reported two cases 
of myocardial infarction after replacement herapy 
with prothrombin complex concentrated, and 
Ritchie et al~6 reported one case of deep venous 
thrombosis in a patient with hemophilia A who was 
given factor VIII concentrate for proximal tibial os- 
teotomy. It is very important to monitor factor VIII 
activity and its inhibitor to avoid not only bleeding 
complications but also thrombic complications. 
Arteriosclerotic disease, either occlusive or aneu- 
rysmal, in a patient with hemophilia will increase as 
the lifespan of these patients is prolonged with ade- 
quate supplemental therapy. Appropriate coagulant 
factor replacement therapy during surgical treatment 
is mandatory to achieve better results in major vascu- 
lar surgery. 
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